Document is current
Any future updates will be listed below
-
Authors
Itagaki, Tadashi
Ueki, Yasushi
Oyama, Yushi
Iguchi, Junko
Fujimori, Koki
Sunohara, Daisuke
Yamamoto, Yuki
Okina, Yoshiteru
Nomi, Hidetomo
Kato, Tamon
Saigusa, Tatsuya
Otagiri, Kyuhachi
Ebisawa, Soichiro
Kuwahara, Koichiro
- License Information
-
More Information
Article History
Received: 27 December 2025
Accepted: 15 April 2026
First Online: 21 April 2026
Declarations
:
: Dr. Ueki reports grant from Astellas Pharma, personal fees from Abbott Vascular, Amgen, Bayer, Daiichi Sankyo, Kowa, NIPRO, and Novartis, outside the submitted work. Dr. Kuwahara has received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Kowa Co., Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Pharma Co., Ltd.), Mitsubishi Tanabe Pharma Corp., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc., and Janssen Pharmaceutical K.K.; funded research or joint research expenses from Kowa Co., Ltd., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Novo Nordisk Pharma Ltd., Amgen, Janssen Pharmaceutical K.K., Parexel International Inc., and Astellas Pharma Inc. His affiliated institution (Shinshu University School of Medicine) has received grants from Otsuka Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Nippon Boehringer Ingelheim Co., Ltd., and Kyowa Kirin Co., Ltd., and his department has endowed chairs from Medtronic Japan Co. Ltd., Boston Scientific Japan K.K., Abbott Japan LLC, Japan Lifeline Co.,Ltd., Biotronik Japan, Terumo Corporation, Nipro Corporation, and Cordis Japan G.K.
: This study was approved by the Ethics Committee of Shinshu University Hospital (approval number: 2023-63) and is registered with the University Hospital Medical Information Network (UMIN 000053786).
